James Molloy analyst ALLIANCE GLOBAL PARTNERS

Currently out of the existing stock ratings of James Molloy, 60 are a BUY (96.77%), 2 are a HOLD (3.23%).

James Molloy

Work Performance Price Targets & Ratings Chart

Analyst James Molloy, currently employed at ALLIANCE GLOBAL PARTNERS, has had 32.35% of price targets met with an average potential upside of 52.73%, reached in 257 days on average. Previously, James Molloy worked at LAIDLAW, JANNEY, SUMMER STREET.

James Molloy has documented 111 price targets and ratings displayed on 19 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on SLS, Sellas Life Sciences Group at 06-Jul-2026.

Wall Street Analyst James Molloy

Analyst best performing recommendations are on PDSB.
The best stock recommendation documented was for PDSB on 5/27/2020. The price target of $4 was fulfilled within 54 days with a profit of $2.78 (227.87%), with a performance score of 42.2.

Average potential price target upside

ICPT HTBX Heat Biologics TNXP ALIM BCDA Biocardia CANF Can Fite Biopharma Ltd ADR OCUP ORMP PSTI Pluristem SLS Sellas Life Sciences Group AVDL Avadel Pharmaceuticals PLC RMTI BDSI BioDelivery Sciences International

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 03-Aug-2023

$19

$19

3 years 1 months 26 days ago
(27-Sep-2023)

8/12 (66.67%)

$19 (0.00%)

435

Hold Since 14-Aug-2023

$19

3 years 1 months 26 days ago
(27-Sep-2023)

1/7 (14.29%)

$19 (0.00%)

41

Hold Since 10-Nov-2020

$19

$13

3 years 1 months 26 days ago
(27-Sep-2023)

8/26 (30.77%)

$19 (0.00%)

246

Buy Since 03-Aug-2023

$19

$20

3 years 1 months 26 days ago
(27-Sep-2023)

2/8 (25%)

$19 (0.00%)

86

Buy Since 10-May-2022

$19

$15

3 years 1 months 26 days ago
(27-Sep-2023)

3/17 (17.65%)

$19 (0.00%)

340

Show more analysts

Stocks James Molloy covered previously. Scores are shown for active stocks only.

ETTX Entasis Therapeutics Holdings NHWK Nighthawk Biosciences QNRX

Please expand the browser size to see the chart

Which stock is James Molloy most bullish on?

Potential upside of $11.34 has been obtained for SLS (SELLAS LIFE SCIENCES GROUP)

What Year was the first public recommendation made by James Molloy?

On 2013
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?